Publications

Stacy Loeb, Rada Mihalcea, Veronica Perez-Rosas, Alex Xu, Jacob Taylor, Nataliya Byrne, Dawn Walter, Marina Ness, Rebecca Robbins, Sylvia Zhang, Trevor Killeen, Divya Natesan, Hala T. Borno. Leveraging Social Media as a Thermometer to Gauge Patient and Caregiver Concerns: COVID-19 and Prostate Cancer. European Urology Open Science. 2021. PMID:


Dixit N, Rugo H, Burke NJ. Navigating a Path to Equity in Cancer Care: The Role of Patient Navigation. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2021. PMID: 33830828


Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. Journal of gastrointestinal cancer. 2021. PMID: 32146619


Ricciuti B, Jones G, Severgnini M, Alessi JV, Recondo G, Lawrence M, Forshew T, Lydon C, Nishino M, Cheng M, Awad M. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). Journal for immunotherapy of cancer. 2021. PMID: 33771889


Kaufman PA, Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Brufsky AM, Rugo HS, Cobleigh M, Swain SM, Tripathy D, Morris A, Antao V, Li H, Jahanzeb M. Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast cancer research and treatment. 2021. PMID: 33641083


Kennedy VE, Ruiz-Cordero R, Jangam D, Wen KW, Dunavin N, Ohgami RS, Bhargava P, Ai W, Fakhri B. A Case of EBV-Negative Aggressive NK-cell Leukemia: Use of Next-Generation Sequencing in Demystifying a Diagnostic Dilemma and Guiding Clinical Care. Clinical lymphoma, myeloma & leukemia. 2021. PMID: 33814335


Sun J, Bok RA, DeLos Santos J, Upadhyay D, DeLos Santos R, Agarwal S, Van Criekinge M, Vigneron DB, Aggarwal R, Peehl DM, Kurhanewicz J, Sriram R. Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models. Metabolites. 2021. PMID: 33652703


Rugo HS, Haltner A, Zhan L, Tran A, Bananis E, Hooper B, Mitra D, Cameron C. Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer. Journal of comparative effectiveness research. 2021. PMID: 33626934


Chaudhuri S, Thomas S, Munster P. Immunotherapy in breast cancer: A clinician's perspective. Journal of the National Cancer Center. 2021. PMID: 39035768


Rabow M, Wang C, Zhang S, Tahir PM, Small EJ, Borno HT. Examining reporting and representation of patients with cancer in COVID-19 clinical trials. Cancer reports (Hoboken, N.J.). 2021. PMID: 33621447


Rabow M, Wang C, Zhang S, Tahir PM, Small EJ, Borno HT. Examining reporting and representation of patients with cancer in COVID-19 clinical trials. Cancer reports (Hoboken, N.J.). 2021. PMID: 33621447


Vadim S Koshkin, Divya Natesan, Li Zhang, David Yoonsuk Oh, Sima P. Porten, Maxwell Meng, Raj Pruthi, Rahul Raj Aggarwal, Eric Jay Small, Lawrence Fong, Terence W. Friedlander. Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy. Journal of Clinical Oncology. 2021. PMID:


Ivan de Kouchkovsky, Li Zhang, Errol Philip, Francis Wright, Daniel Myung Kim, Divya Natesan, Daniel Kwon, Hansen Ho, Son Ho, Emily Chan, Sima P. Porten, Arpita Desai, Franklin W. Huang, Jonathan Chou, David Yoonsuk Oh, Raj Pruthi, Lawrence Fong, Eric Jay Small, Terence W. Friedlander, Vadim S Koshkin. TERT promoter mutation as a prognostic marker in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors. Journal of Clinical Oncology. 2021. PMID:


Daniel Kwon, Rohit Vashisht, Hala Borno, Rahul Raj Aggarwal, Eric Jay Small, Atul Butte, Franklin W. Huang. Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: A University of California (UC) Health System registry study. Journal of Clinical Oncology. 2021. PMID:


Hala Borno, Sylvia Zhang, Scarlett Lin Gomez, Celia Kaplan, Christine Miaskowski, Julian Hong, Dame Idossa, Adina Bailey, Eric Jay Small. Assessing the impact of the COVID-19 pandemic on patients with genitourinary malignancies. Journal of Clinical Oncology. 2021. PMID:


Ronald C. Chen, Theodore Karrison, Colleen Anne Lawton, William Adrian Hall, Hala Borno, Mihaela Rosu, Ashesh B. Jani, David M. Schuster, Michael J. Seider, Jason A. Efstathiou, Edwin Melencio Posadas, Paul L. Nguyen, Felix Y Feng. INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy. Journal of Clinical Oncology. 2021. PMID:


Hala Borno, Patricia Li, Sylvia Zhang, Dame Idossa, Arpita Desai, Tammy J. Rodvelt, Rohit Bose, Vadim S Koshkin, Jonathon Chou, Terence W. Friedlander, Franklin W. Huang, Eric Jay Small, Rahul Raj Aggarwal. Implementation of clinician-facing prostate cancer therapeutic clinical trial decision tool at a comprehensive cancer center. Journal of Clinical Oncology. 2021. PMID:


Barry Tong, Hala Borno, Fern Alagala, Kelly Gordon, Eric Jay Small, Amy M. Lin, Amie Blanco, Mallika Sachdev Dhawan. Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer. Journal of Clinical Oncology. 2021. PMID:


Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2021. PMID: 33617937